Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases.
Our vision is to make precision medicine available to physicians and patients for the treatment of cancers and other difficult-to-treat diseases.
We are working to provide clinicians with an accurate and improved way to select the patients who may receive the greatest benefit from a particular therapy. Because our values are founded on improving the health of patients, we strive to achieve targeted drug delivery to diseased cells to improve effectiveness of therapy and reduce undesirable side effects.
Closing share price
|FY, 2015||FY, 2014||FY, 2013|
|$70 K||$70.4 M||$64.9 M|
|$-41.3 M||$5.46 M||$-18 M|